Wolfram Brugger
AstraZeneca
18 Papers
46 Citations
Wolfram Brugger is an academic researcher from AstraZeneca. The author has contributed to research in topics: Medicine & Abiraterone acetate. The author has an hindex of 6, co-authored 18 publications.
Chat about Author
Papers
Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study.
Mathias J. Rummel,Georg Maschmeyer,Arnold Ganser,Andrea Heider,Ulrich von Gruenhagen,Christoph Losem,Gerhard Heil,Manfred Welslau,Christina Balser,Ulrich Kaiser,Eckhart Weidmann,Heinz Dürk,Harald Ballo,Martina Stauch,Wolfgang Blau,Alexander Burchardt,Juergen Barth,Frank Kauff,Wolfram Brugger +18 more
TL;DR: In this article, the authors compared B-R and CHOP-R as first-line treatment in patients with indolent lymphomas or mantle cell lymphoma and presented updated results for overall survival (OS), time-to-next-treatment (TTNT), and secondary malignancies (sNPL) with a median follow-up of 113 months.
72
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.
Bristi Basu,Matthew G Krebs,Raghav Sundar,Raghav Sundar,Richard H. Wilson,James Spicer,Robert H. Jones,Michael Brada,Denis Talbot,N. Steele,A.H. Ingles Garces,Wolfram Brugger,Elizabeth A. Harrington,Joseph R. Evans,Emma Hall,Holly Tovey,F.M. de Oliveira,Susana Carreira,Karen E Swales,Ruth Ruddle,Florence I. Raynaud,Beth Purchase,J.C. Dawes,Mahesh K. B. Parmar,Alison Turner,Nina Tunariu,Susana Banerjee,J.S. de Bono,Udai Banerji +28 more
TL;DR: A highly active and well-tolerated combination of vistusertib, administered as an intermittent schedule with weekly paclitaxel, in patients with HGSOC and SqNSCLC is reported.
33
Phase I trial of olaparib (PARP inhibitor) and vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian and triple negative breast cancer.
Shannon N. Westin,Jennifer K. Litton,Rochelle A Williams,Christopher J. Shepherd,Wolfram Brugger,Elizabeth Janet Pease,Pamela T. Soliman,Michael Frumovitz,Charles F Levenback,Anil K. Sood,Larissa A. Meyer,Stacy L. Moulder,Vicente Valero,Sadia Saleem,Anna Marie Rodriguez,Annies Cyriac,Laverne Engerman,Christine Samuel,Gordon B. Mills,Robert L. Coleman +19 more
TL;DR: The recommended phase II dose (RP2D) of olaparib and vistusertib is determined and molecular markers of response are evaluated and two oral schedules for V are presented.
24
A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies.
Simon Rule,Arnon P. Kater,Tim H. Brümmendorf,Christopher Fegan,Martin Kaiser,John Radford,Stephan Stilgenbauer,Sabine Kayser,Martin J. S. Dyer,Peter Brossart,Justin Cidado,Lisa Drew,Joe Birkett,Andrew Davies,Wenlin Shao,Wolfram Brugger +15 more
TL;DR: This data indicates that phosphorylation of RNA Polymerase II at serin level contributes to transcription elongation inCDK9 and this data points to a dual role for EMT in transcription-regulating CDKs.
11
An open-label, multidrug, biomarker-directed, multicentre phase II umbrella study in patients with non-small cell lung cancer, who progressed on an anti-PD-1/PD-L1 containing therapy (HUDSON).
John V. Heymach,Michael Thomas,Benjamin Besse,Patrick M. Forde,Mark M. Awad,Glenwood D. Goss,Keunchil Park,Naiyer A. Rizvi,Si-Houy Lao-Sirieix,Sabina Patel,Peter G. Mortimer,Helen Ambrose,Philip J. Jewsbury,Kris Sachsenmeier,Leila Khoja,Wolfram Brugger +15 more
TL;DR: This data indicates that once-weekly dosing of immune checkpoint inhibitor containing regimens with or without chemotherapy significantly improves survival outcomes in first- and second-line non-small cell lung cancer patients.
9